Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the disease.

We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

Alzheimer’s disease remains one of medicine’s toughest challenges, affecting millions and costing trillions of dollars ...

With so few Alzheimer's drugs available, repurposing medications approved for other conditions could be the key to tackling ...

Scientists at UCSF and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that ...

A new online tool developed by researchers at the University of Louisville promises to speed up the discovery of treatments ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

New data shows no increased cardiovascular risk of the osteoporosis drug vs anabolic agents — and even suggests a lower risk.